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1. Introduction
Giardiasis continues to be a significant parasitic disease in the world caused by the species 
of Giardia genus, particularly Giardia intestinalis, which affects humans and animals in a wide 
clinical spectrum, with zoonotic potential due to shared genotypes that can affect the same 
hosts. This protozoan disease occurs in developing as well as in industrialized countries, also 
affecting travelers. In recent years, multiple aspects in its epidemiology, but also and par-
ticularly in the long-term clinical consequences, have been highlighted. In this introductory 
chapter, a review on general aspects, based on recent experiences, is described.
2. Overview and general aspects of giardiasis
Giardia was described and was associated with the symptoms in 1681 for the first time when 
the Dutchman, Van Leeuwenhoek, found the trophozoites in his own feces; nevertheless, just 
until 1859, the first report was credited to the Czech Vilém Lambl [1–3]. Giardia intestinal is a 
flagellated protozoon (also known as G. lamblia or G. duodenalis) and is a tiny and ubiquitous 
intestinal and/or biliary parasite, which affects mammals, such as humans, pets, and livestock 
by inhabiting the upper part of the small intestine [4–6]. Frequently, this parasite contami-
nates water sources worldwide especially in temperate and tropical locations where sanitary 
conditions are suboptimal; for this reason, giardiasis is the commonest parasitic infection of 
the gastrointestinal tract, the most important responsible for outbreaks of diarrhea and spo-
radic endemic disease [7, 8].
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3. Epidemiology
Distributed worldwide, Giardia is probably the most frequent pathogenic intestinal proto-
zoon in children and adults, and one of the most common nonviral causes of diarrhea, afflict-
ing annually an approximate 280 million individuals. Due to its intensifying global burden 
and its developmental and socioeconomic impact on infected individuals, this parasitosis 
was incorporated in the Neglected Disease Initiative of the World Health Organization in 
2004 [4, 7, 9, 10].
In developed countries, giardiasis is associated with social and climatic factors and is referred 
as a re-emerging infectious agent. Some epidemiological studies have shown that its preva-
lence varies between the population studied and the location, from 2 to 5% on industrialized 
countries to 20–30% in developing countries [1, 5, 11], and these changes in prevalence are 
associated, among others, with the hygiene infrastructure and the impact of the weather 
conditions, reason why environmental control efforts are necessary, which requires an inte-
grated and systematic approach to decrease and mitigate the influence on the disease epi-
demiology; for this reason, it is linked to educational programs and other interventional 
measures [2, 6, 12].
Although in Latin America, a restricted quantity of population-based studies has been per-
formed, in Cuba, according to the last national intestinal parasites survey (n = 5850), the prev-
alence of Giardia lamblia infection was determined to be at 6.02% (95%CI 5.40–6.63) [13].
This parasitosis is highly infectious where Giardia cysts are habitually excreted in consider-
able population, especially in young children after ingestion of contaminated water or food 
and through person-to-person contact. Cysts can survive for months in cold water, and they 
are relatively resistant to chlorination, reason why between 10 and 100 cysts are sufficient to 
establish infection 100% of the time. Consequently, ingestion of water or food that contains 
small levels of contamination can result in the disease, which is more recurrent in summer 
and fall. Other usual ways to transmit them could be among day care center attendees and 
people who live in residential institutions, and it could also spread by means of sexual activ-
ity, by oral-anal contact [1, 5, 11, 12].
4. Life cycle
Giardia intestinalis is a noninvasive protozoan parasite with a simple life cycle and a sim-
plified metabolism that depends on the host for nutrients such as purines, pyrimidines, 
cysteine, and cholesterol. The genus Giardia and its life cycle are relatively well recognized 
and clearly defined; members of the genus are flagellated protozoans belonging to the class 
Zoomastigophorea and order Diplomonadida, which lives and multiplies by asexual multi-
plication frequently on the luminal surface of the small intestine of its vertebrate host [14–16].
The trophozoite, which is 9–21 μm long, 5–15 μm wide, and 2–4 μm thick, lives in the small 
intestine and is responsible for many manifestations of the disease. The cytoskeleton composed 
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of unique families of structural proteins and carbohydrates involves two nuclei, a ventral 
sucking adhesive disk by which it may adhere to intestinal epithelial cells, a median body, 
and four pairs of flagella that behave differently during motility. The dorsal surface is pear 
shaped and bilaterally symmetrical, with the two highly characteristic nuclei best visualized 
after staining. The newly emerged trophozoites infect the duodenum and jejunum where 
there is a favorable alkaline pH; they attach intimately to the intestinal epithelium by their 
ventral disk and begin to multiply by binary fission. Detection of soluble cyst wall proteins in 
the feces forms the basis of many stool antigen assays [1, 8, 16, 17].
Giardia takes advantage of host conditions at each step of its descent through the human 
gastrointestinal tract. After ingestion, Giardia infection is initiated by the acidic milieu in the 
stomach and the presence of bile and trypsin in the duodenum, and then, it reproduces in 
the small intestine, yielding two trophozoites from each cyst, which quickly divide again. 
Exposure of cysts to gastric acid triggers excystation, although the “excyzoites” do not 
emerge from the cyst until it passes into the small intestine. In vitro trophozoites double in 
number every 6 hours in the fastest growing isolates. The emerging parasites (excyzoites) 
quickly transform into trophozoites that attach to the intestinal epithelial cells using the 
adhesive disk, which is a major virulence factor; in this way, any excreted cysts are mature, 
highly infectious, and quite resistant to disinfectants routinely used for water treatment 
such as chlorine [8, 16, 18].
When the trophozoite senses a change in the environment as the cell is transported further 
down in the small intestine, it starts the encystation; in the earliest moment of this process, 
some specific vesicles are designed that allow its development and maturation, probably as 
a result of cholesterol starvation. At the same time with several proteins implicated in meta-
bolic pathways, after that, several proteins also change their expression by important gene 
expression changes. Giardia has a considerable metabolic capacity as another parasite that 
lacks pathways for de novo biosynthesis of pyrimidines and purines for nucleotide salvage, 
but this process is conditioned by oxygen concentration, despite anaerobic metabolism and 
generating reactive oxygen species (ROS) by the host [1, 14–17].
Giardiasis as a multifactorial disease involves in its pathobiology complex interactions 
between host and parasite, differences in nutritional status, immune status, co-infections, and 
intestinal normal flora that could contribute to the differences in disease outcome observed 
among individuals from developing against developed countries. The roles of the host’s 
intestinal normal flora and co-infections during Giardia infections are still largely unascer-
tained [3, 12, 15, 19].
Some morphologically identical but genetically distinct Giardia infect humans and animals 
that now are divided into eight assemblages (A–H) what could bring a clarification about 
infection outcome. Thus, assemblages A and B are found in human and other animals, being 
considered zoonotic, whereas the other assemblages display host specificity and do not infect 
humans (C and B in dog, F in cat, E in hoofed animal, G in rodents, and H in sea mammals). 
Interestingly, this proportion is not altered when comparing data from developing and devel-
oped countries, but the prevalence of mixed infections is higher in the developing countries 
[8, 15–18].
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The two assemblages (A and B) are composed of genetically distinguishable isolates, which 
may vary in infectivity, antigenicity, and virulence. In addition, human hosts vary in suscepti-
bility to infection and disease and in the response to tolerance to infection. In this way, Giardia 
is an intraluminal parasite that adheres to the epithelium by way of an adhesive or sucking 
disk, although invasion of the epithelium either does not occur or is rare. Meanwhile, the 
number of trophozoites in the intestine can be so large that adherent organisms cover much 
of the epithelial surface. This could disrupt the epithelial brush border and contribute to lack 
of disaccharidase as could be seen in some patients [8, 14, 15].
5. Clinical aspects
The clinical manifestations, course, and duration of Giardia infections are variable. In that 
way, infections may be self-limited or persistent, asymptomatic, or symptomatic. Usually, 
most patients remain asymptomatic, but when signs and symptoms occur and acute disease 
is established, manifestations happen normally in travelers and in outbreaks, and they are 
characterized by diarrhea, nausea, anorexia, dehydration, flatulence, eructation, distention, 
abdominal cramping, and weight loss. Contradictorily, fever and vomiting are uncommon 
[7, 13, 20].
The first signs of infection appear after 6–15 days. Most symptomatic infections resolve 
spontaneously; however, sometimes, hospitalization is required when infections have long-
term consequences and do not respond to the normal treatment. Chronic Giardia infections 
are reported frequently in nonendemic areas and also could result in irritable bowel syn-
drome, food allergies, arthritis, aphthous ulcers, or chronic fatigue syndrome after resolution 
[3, 10–12].
In some cases, if acute symptoms are not treated on time, they can develop into a chronic 
stage, which can affect all age groups but children are at higher risk, in whom Giardia infec-
tions have been associated with lower serum level of zinc, iron, and vitamins (A, B12, and 
folate); despite similar anthropometric indicators among infected and uninfected individu-
als in early childhood, the failure to thrive and poor cognitive function are characteristics in 
them. Furthermore, the loss of lactose is common and can persist for some weeks after treat-
ment, which is why it is necessary to be distinguished in symptomatic patients from relapse 
or reinfection. In extreme cases, malabsorption and weight loss are severe and mimic sprue 
[1, 2, 8].
A typical scenario is a mildly to moderately ill person who grumbles of a raised number of 
urgent loose stools, with flatus, cramping, anorexia, and weight loss. There may even be peri-
ods when the person feels better only to relapse and then become noticeably worse. Finally, 
after some days to several weeks, the person will seek medical help. Similar to other causes 
of infectious diarrheas, symptoms can carry on after successful treatment and evolve into 
irritable bowel syndrome and chronic fatigue, even 6 years after the infection. Infrequently, 
Giardia is also found in biliary and pancreatic ducts and can cause cholecystitis and pancreati-
tis, and other localizations reported are the urinary tract, gastric mucosa, and colonic and ileal 
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mucosa. Extraintestinal manifestations and long-term consequences are unusual, but a series 
of sporadic cases documented them in a third of the patients. The signs can include rash, reac-
tive arthritis, eye complaints, and cognitive deficiencies [1, 2, 9, 10, 20].
6. Diagnostics
The diagnosis of giardiasis is based on the detection of cysts, trophozoites, or parasite-specific 
antigens in fecal microscopic examination, complemented with microscopic examination of 
duodenal fluids or in other biological samples. Polymerase chain reaction has been largely 
experimental, but it is being increasingly used in field and laboratory settings; considering 
that excretion of cysts may be variable or in low concentrations (50–80% sensitive), two or 
three checkups may be necessary, leading to a late diagnosis (>2 weeks) [3]. Stool antigen 
tests are standard in most laboratories and are highly sensitive (>90%), specific (~100%), and 
relatively inexpensive and do not require a trained microscopist [2, 9, 13, 18].
The observation of small intestine biopsy specimens or intestinal contents for trophozoites 
was the previous “gold standard” for diagnosis, but now, it is uncommonly needed to estab-
lish or to confirm the diagnosis. A number of morphological characteristics of the trophozoite 
can be used for the initial diagnostic, but it is not possible to identify which specific species by 
light microscopy, the reason why another type of test could be used in the medical approach. 
Electron microscopy might be useful for the identification of some Giardia species, but it is not 
applicable for screening or routine use [15, 18].
The use of immunological methods offers an important alternative for the diagnosis. The 
use of fluorescence microscopy and the direct fluorescence antibody test, which recognizes 
surface epitopes on cysts, has been reported to achieve relatively high specificity (99.8–100%) 
and sensitivity (93–100%) for the detection. The detection of Giardia antigens in fecal samples 
is another approach. Various enzyme-linked immunoassays have been used and report speci-
ficities of 87–100% and sensitivities of 63–100%. Flow cytometry is another technique to iden-
tify the Giardia cysts when immunofluorescent staining and microscopic examination and/or 
enumeration report unsatisfactory results [15, 18].
In some cases, the laboratory findings are nonspecific, and in low-intensity infections, testing 
methods can be false negative for which it is required to repeat the test. On the other hand, 
the white blood cell count and liver function test results used to be normal. The electrolyte 
disturbances could be present if diarrhea and vomiting are severe. White blood cells, lactofer-
rin, blood, and mucus are not found in stools. Immunoglobulin levels are usually normal but 
usually low or absent in susceptible hypogammaglobulinemic individuals [2, 3].
7. Treatment
During the last 60 years of the past century, the arsenal of antigiardial drugs has been increas-
ing, and they still are in use. Before the introduction of quinacrine, these infections were 
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treated with mercury, carbon tetrachloride, arsenicals, and bismuth; at present, an impor-
tant number of agents have shown to be efficacious against Giardia in vitro and clinically. 
Nevertheless, current investigations try to establish an appropriate treatment regimen in 
giardiasis, but none of them appear to fulfill most of the criteria for an ideal drug. In fact, 
giardiasis is regularly considered an easily treated infection, but at times, due to treatment 
failure, re-infection or postinfection syndromes can have a huge impact on quality of life of 
the patient, which is why it is important to know at least six different classes of drugs, with 
different mechanisms, indication, and contraindications [1, 2, 21].
The 5-nitroimidazole (5-NI) derivatives remain the most frequently prescribed drugs, as well 
as metronidazole, tinidazole, and secnidazole. In spite of their efficacy, the treatment with 
these drugs is associated with several adverse effects, which are not always tolerable such 
as headache, metallic or bitter taste in mouth, nausea, vomiting, diarrhea, dizziness, general 
body discomfort, loss of appetite, etc. Whereas medical opposition may limit the use of some 
of them in singular cases, as in pediatrics, where their dose requirements make difficult the 
administration of tablet formulations to children. Finally, in the follow-up of some patients 
after treatment to evaluate the response to antigiardial drugs, a therapeutic failure is identi-
fied [4, 7, 21, 22].
Nitazoxanide is a new very broad spectrum 5-nitrothiazolyl derivative with a potentially use-
ful activity against a range of biological agents. The effect of nitazoxanide in Giardia tropho-
zoite includes ultrastructural changes in the cell morphology, swelling, and the formation of 
large empty areas in the cytoplasm and the disruption of the plasma membrane. An overall 
response rate of 75–94%, usually well tolerated, and a few adverse effects are the reason to 
choose this medicament [1, 22].
Some patients, who are being treated with the standard treatment that cures other patients, 
can continue with symptoms. In these cases, there are possibilities of different situations, 
including drug resistance, cure followed by reinfection, and also noncompliance and post-
Giardia lactose intolerance, because when a drug-resistant giardiasis is identified, the stage 
changes and it is necessary to use another antigiardial compound with a different mechanism 
of action or a drug combination [1, 2, 4].
When there is a resistant Giardia, some therapeutic strategies could be used, since increasing 
the alternative dose and/or duration of the same one, changing another antigiardial, or using 
a drug combination might exert the synergistic effects. For this reason, the combination of 
the therapy should be reserved when single primary agents have failed to clear the infection. 
However, it also should be considered that administration of two or three drugs may have 
more profound physiological consequences, alter the intestinal microbiota, and increase the 
drug-related adverse events and health care costs [8, 9, 22].
8. Control and prevention
The interest in Giardia infection studies have been raising since its inclusion in the World 
Health Organization (WHO) in the Neglected Diseases Initiative in 2004 [9, 19]. In the same 
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way, a bibliometric study of scientific production on giardiasis reports 6964 papers between 
1971 and 2010 available in PubMed, written in 27 different languages corresponding to origi-
nal articles (78.5%), reviews (8.6%), case reports (6.8%), and letters to the editors (3.6%) that 
evidenced a steady growth of literature dedicated to Giardia and its infection throughout the 
40-year analyzed period [7].
This pathogen has been highlighted for the importance in terms of patient well-being and 
its effects on quality of life for being a continuing cause of the patient’s discomfort and pain. 
Unfortunately, due to a lack of political will, funding, interest from the scientific community, 
or the combination of all of these factors, giardiasis is not a health priority; that is why, it is 
important to take in mind that this infection is prevented by a scrupulous personal hygiene, 
proper disposal of sewage, removal or killing of cysts from water supplies, and preventing 
contamination of food and water [2, 20].
Actually, the global burden of chronic giardiasis is not known, and the difficulties in diag-
nostic tools, the lack of definition, and difficulties to quantify the impact of an infection that 
causes an acute or chronic one, principally symptomatic illness, contribute to the necessity to 
realize studies that estimate the problems in terms of cost, day lost for disability, and quality 
of life [9, 18].
Despite that, important contributions have been made regarding the spectrum of illness 
attributable to giardiasis. It is illustrated in the protective effect of Giardia against other types 
of diarrhea what could be due to the anti-inflammatory activity of Giardia. Nevertheless, fur-
ther investigations on the pathogenic mechanisms are needed that could lead to potential 
interventions preventing the severe illness [2, 11].
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